This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Amarin Corporation plc
Drug Names(s): Sublingual Apomorphine
Description: Apokyn is a nonergoline dopamine agonist that provides rapid absorption of apomorphine directly into the bloodstream after sublingual (under the tongue) administration. Dopamine agonists imitate the action of dopamine rather than replace it in the way levodopa does. Dopamine is known as a neurotransmitter. It enables the brain to transmit signals from one area to another, which allows the brain to control and co-ordinate body movements.
Deal Structure: In May 2006, Amarin Corporation announced the acquisition of global rights to a novel oral, sublingual formulation of apomorphine. Amarin acquired the rights to the new formulation from its Vice President of Clinical Development, who invented the novel formulation and filed the related patent prior to joining Amarin.
The transaction consideration comprises a small upfront payment, success milestones on the advancement of the development program to regulatory approval and royalties upon commercialisation. Specific terms are not disclosed.
Sublingual Apomorphine News
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: